Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Angelos M. Stergiou is President and CEO at Sellas Life Sciences Group. OQRO lists 1 transaction filed with the SEC under this name, the latest on Nov 21, 2026, each linked to the official Form 4.
President and CEO
Disclosures on record
1
Companies involved
1
Nov 18, 2026Sold~$510Kdisclosed Nov 21
DetailsOfficial recordAngelos M. Stergiou has no open-market purchase on record since 2018. Sales in 4 of the 9 years since 2018.
Angelos M. Stergiou reported 0 open-market purchases and 4 sales since 2018; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $510K1×1 trade |
| 2022 | — | $17K1×1 trade |
| 2021 | — | $13K1×1 trade |
| 2018 | — | $29K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Angelos M. Stergiou reported holding 1,734,896 shares of Sellas Life Sciences Group (SLS), worth about $23.7M at the last close of $14 (Nov 20, 2026). In the last 12 months, Angelos M. Stergiou sold $510K in 1 sale.
Sellas Life Sciences Group's proxy statement reports total compensation of $1.88M for Angelos M. Stergiou for fiscal year 2025. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 23, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Sellas Life Sciences Group SLS | 1,734,896 | 1.73M direct | $14 | $23.7M | Nov 18, 2026 |
Is this Angelos M. Stergiou’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Angelos M. Stergiou reported 0 open-market purchases and 4 sales here, 2018 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Nov 18, 2026, Angelos M. Stergiou reported holding 1,734,896 shares of Sellas Life Sciences Group (SLS). At the last close of $14 on Nov 20, 2026, that is about $23.7M. This is the stake disclosed in filings, not a net worth.
No public filing gives Angelos M. Stergiou's net worth. What SEC Form 4 shows is the stock stake: 1,734,896 shares of Sellas Life Sciences Group (SLS), about $23.7M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
In SEC filings of the last 12 months, Angelos M. Stergiou reported 1 open-market sale worth $510K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Sellas Life Sciences Group's proxy statement reports total compensation of $1.88M for Angelos M. Stergiou for fiscal year 2025. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Angelos M. Stergiou has no open-market purchase on record since 2018. Sales in 4 of the 9 years since 2018.
In SEC filings since 2018: no open-market purchase is on record; the latest open-market sale is from 2026.
Sellas Life Sciences Group (SLS), from 2018 to 2026: 0 purchases and 4 sales.